Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqGS - Delayed Quote USD

Savara Inc. (SVRA)

Compare
3.0100
+0.1500
+(5.24%)
At close: 4:00:01 PM EDT
2.9900
-0.02
(-0.66%)
After hours: 5:21:31 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for SVRA

Recent News: SVRA

View More
Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
Business Wire 6 days ago

Savara Gets Up to $200 Million Loan From Hercules Capital
PREMIUM
MT Newswires 7 days ago
Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital

Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital
Business Wire 7 days ago
Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Business Wire 7 days ago
Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025

Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025
Business Wire 16 days ago
Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Business Wire 27 days ago
Savara Announces Participation in the Leerink Global Healthcare Conference

Savara Announces Participation in the Leerink Global Healthcare Conference
Business Wire 30 days ago
Savara Announces New Employment Inducement Grant

Savara Announces New Employment Inducement Grant
Business Wire last month
Positive Signs As Multiple Insiders Buy Savara Stock

Positive Signs As Multiple Insiders Buy Savara Stock
Simply Wall St. last month
Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research

Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research
Business Wire 2 months ago
Savara Announces Participation in Upcoming Healthcare Investor Conferences

Savara Announces Participation in Upcoming Healthcare Investor Conferences
Business Wire 2 months ago
View More

Related Tickers

THAR Tharimmune, Inc.
1.2900
-1.53%
 
CMPX Compass Therapeutics, Inc.
1.6900
-24.55%
 
KROS Keros Therapeutics, Inc.
10.04
+5.13%
 
PHGE BiomX Inc.
0.6290
+27.59%
 
AARD Aardvark Therapeutics, Inc. Common Stock
9.35
+12.79%
 
TECX Tectonic Therapeutic, Inc.
17.89
+6.24%
 
EWTX Edgewise Therapeutics, Inc.
15.52
-22.90%
 
TARS Tarsus Pharmaceuticals, Inc.
51.49
+5.25%
 
VERA Vera Therapeutics, Inc.
23.59
+7.13%
 
SPRO Spero Therapeutics, Inc.
0.7060
+1.73%